Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Carboxypeptidase B2 (CPB2), also known as Carboxypeptidase U (CPU), Plasma carboxypeptidase B (pCPB), or Thrombin-activatable fibrinolysis inhibitor (TAFI), is a human enzyme that plays important roles in regulating fibrinolysis and modulating the activity of biologically active peptides. It is a metallocarboxypeptidase that cleaves C-terminal basic amino acids, specifically arginine or lysine, from peptides and proteins. CPB2 is synthesized as an inactive zymogen and activated by proteolytic cleavage. After activation, it downregulates fibrinolysis by reducing plasminogen binding to fibrin and regulates peptide hormones by cleaving C-terminal arginine or lysine residues. Genetic polymorphisms in CPB2 may influence individual susceptibility to thrombosis or bleeding disorders.
Inhibition of carboxypeptidase activity, modulation of fibrinolysis, regulation of peptide hormone activity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Carboxypeptidase B2 (CPB2).